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Abstract 
The Epidermal Growth Factor Receptor (EGF-R) becomes constitutively tyrosine phosphorylated on two novel sites in v-Src 
transformed cells, and these phosphorylations are associated with enhanced signaling activity [1]. To determine whether Src could directly 
phosphorylate hese sites, we have examined the ability of the Src kinase to phosphorylate both wild-type and kinase-defective EGF-Rs in 
vitro. Although purified Src could phosphorylate EGF-Rs, the pattern of phosphorylation sites was not identical to what was previously 
found in vivo [1]: Src in vitro directly phosphorylated EGF-Rs on one autophosphorylation site (Tyr 1173) which was not a site of 
Src-induced in vivo phosphorylation, suggesting the in vivo inaccessibility of this site. One Src-specific in vitro phosphorylation site (Tyr 
703) appeared to correspond to one of the in vivo Src-induced sites (sPY2), but the other Src-specific in vivo site (sPY1) was not 
significantly phosphorylated in vitro, raising the possibility of a Src-induced tyrosine kinase cascade. The ability of Src to phosphorylate 
the EGF-R is consistent with the suggestion that the receptor can function as a kinase substrate independent of its intrinsic enzymatic 
activity, as implied by recent studies on signaling by kinase-defective EGF-Rs. 
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1. Introduction 
The epidermal growth factor receptor (EGF-R) is a 170 
kDa cell surface glycoprotein which contains a single 
membrane spanning region [2] and intrinsic tyrosine kinase 
activity. After ligand-induced dimerization [3], the recep- 
tor's intracellular tyrosine kinase domain becomes acti- 
vated and proceeds to transphosphorylate other co-clus- 
tered receptors on five autophosphorylation sites in the 
carboxy-terminal domain. After EGF-R autophosphoryla- 
tion on tyrosine residues 992, 1068, 1086, 1148, and 1173 
[4-6], the activated receptors phosphorylate many well 
characterized substrates and the EGF-R signal transduction 
cascade proceeds. 
Transformation of cells by expression of oncogenes, 
such as v-Src, induces cells to grow, while reducing or 
eliminating their dependence on growth factors. For exam- 
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pie, BALB/MK-2 mouse epidermal keratinocytes are cells 
which have been demonstrated to require epidermal growth 
factor (EGF) for proliferation; expression of the v-Src 
oncogene liminates the EGF requirement of these cells 
[7]. Therefore, v-Src expression has a positive effect on, or 
might be able to substitute for, EGF-R function. 
Although the presence of EGF-R expression in cells is 
not required for v-Src transformation [8], the EGF-R is a 
candidate substrate for the tyrosine kinase activity of v-Src. 
EGF-Rs in src-transformed cells show a significant eleva- 
tion in tyrosine phosphorylation, as well as phosphoryla- 
tion on serine and threonine residues [1]. Specifically, 
v-Src induces tyrosine phosphorylation on two non-auto- 
phosphorylation sites on the EGF-R in vivo, in the pres- 
ence or absence of ligand stimulation. 
The expression of v-Src in cells does not affect ligand- 
induced EGF-R autophosphorylation or change the ligand 
binding affinity for EGF. However, when both v-Src and 
EGF-Rs are expressed in rat fibroblast ceils, phospholipase 
C- T (PLC- T) becomes constitutively phosphorylated, even 
in the absence of EGF (40-70% of what is detected with 
EGF stimulation) [1]. Since v-Src alone does not directly 
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bind or significantly phosphorylate PLC-% it is likely that 
v-Src induces the activation of EGF-R tyrosine kinase 
activity in the absence of ligand. Therefore, v-Src induced 
phosphorylation f the receptor may be able to bypass the 
normal requirement of ligand binding for the generation of 
some or all of EGF-R cellular actions. 
In this current study, we analyzed the sites on the 
EGF-R which are directly phosphorylated in vitro by 
immunoprecipitated v-Src or by Baculovirus-expressed im- 
muno-purified c-Src. By examining Src phosphorylation f 
kinase-defective and wild-type EGF-Rs, it was possible to 
determine whether Src directly phosphorylates the EGF-R 
in vitro, and whether any in vitro sites of phosphorylation 
are similar to sites phosphorylated in v-Src transformed 
cells or in response to ligand. 
We have determined that in vitro, immunopurified Src 
phosphorylated one autophosphorylation site(PI) and one 
additional site (Tyrosine 703) on the EGF-R. The auto- 
phosphorylation site was not detectably phosphorylated by
Src in vivo, whereas the other site appeared to correspond 
to one of the sites of Src-induced in vivo phosphorylation. 
The ability of Src to phosphorylate he EGF-R may pro- 
vide additional ways in which the EGF-R could be regu- 
lated or transmit signals. Moreover, the fact that Src 
induces in vivo phosphorylation f a site which is not a 
site of in vitro phosphorylation raises the possibility that 
EGF-R phosphorylation in Src-transformed cells could in- 
volve a tyrosine kinase cascade. 
2. Materials and methods 
2.1. Cell culture 
The B82L parental cells and the B82L cells expressing 
the human wild-type (Lys 721) EGF receptor and the 
mutated, kinase-defective (Met 721) EGF receptor were a 
generous gift from Dr. G.N. Gill (University of California, 
San Diego, CA) and have been described previously [9]. A 
mutant dihydrofolate r ductase gene provides a dominant 
selectable marker for the B82L cells overexpressing the 
EGF receptor [10]. These cells were maintained in c~- 
minimum essential medium (Gibco Labs.) containing 10% 
dialyzed fetal bovine serum and 2 mM methotrexate. Be- 
fore experiments, the cells were kept in the absence of 
methotrexate (in Dulbecco's modified Eagle medium 
(DMEM) containing 10% fetal bovine serum) for at least 
24 h. The B82L parental cells were maintained in DMEM 
containing 10% fetal bovine serum. Ratl fibroblasts trans- 
formed by the expression of chicken v-Src (R1 v-Src) were 
maintained in DMEM containing 10% fetal bovine serum. 
2.2. In vitro kinase assays 
Cells expressing EGF-R or v-Src were washed twice 
with ice cold phosphate-buffered saline (PBS) and solubi- 
lized in lysis buffer containing 50 mM Tris pH 7.4, 150 
mM NaCI, 1% Nonidet P-40, 0.25% NaDOC, 1 mM 
EDTA, 1 mM Na3VO4, 10/xg/ml pepstatin A, 50/zg/ml 
leupeptin, 0.02 TIU/ml of aprotinin, 1 mM phenylmethyl- 
sulfonyl fluoride, 40 mM 4-nitrophenyl phosphate Na 2 salt 
(PNPP). Insoluble material was removed by centrifugation 
at 4°C for 15 min at 14000 rpm. Supernatants containing 
equal amounts of protein (500 /zg) were incubated for 2 
hours at 4°C with 100 /~I of washed Protein G-agarose 
(Boehringer Mannheim) and a specific mouse monoclonal 
antibody. After washing the immunoprecipitates three times 
with lysis buffer and two times with 1 X kinase buffer (20 
mM Pipes, pH 7.2, 10 mM MnC1 z, 50/zM Na3VO 4 ), the 
EGF-R immunoprecipitation pellets were used alone or 
mixed with either the v-Src immunoprecipitation pellets or 
with 5/xg of immunopurified Baculovirus-expressed c-Src. 
Then 50 /xl kinase buffer containing [3,-32p]ATP (20 mM 
Pipes pH 7.2, 10 mM MnC12, 50 /zM Na3VO 4 and 10 
/xCi [y-32p]ATP) was added to the samples. The samples 
were incubated at 30°C for 20 min, 25 ml of 3X Laemmli 
sample buffer was added, and the samples were boiled for 
2 min. The samples were then analyzed by SDS-PAGE 
and the gel was either exposed to film directly or trans- 
ferred to nitrocellulose and then exposed to film. The 
samples in Fig. 1 have been transferred to nitrocellulose. 
However, thin layer chromatography (TLC) and high per- 
formance liquid chromatography (HPLC) were done on 
EGF-R proteins which were extracted from gel slices. 
Neither cells nor receptors were exposed to EGF in the 
experiments reported here. In our prior work [1] we showed 
that in vivo EGF-R tyrosine phosphorylation sites induced 
by ligand and those induced by Src were non-overlapping 
and additive. 
The following antibodies were used: 108, an anti-hu- 
man EGF-R monoclonal ntibody for immunoprecipitation 
(Dr. J. Schlessinger, New York University Medical Center, 
NY) and EC10, an anti-v-Src monoclonal antibody for 
immunoprecipitation and immunoblotting (Dr. S. Parsons, 
University of Virginia). 
The Baculovirus c-Src vector was generously supplied 
by Dr. D.O. Morgan (University of California, San Fran- 
cisco) and the Src was purified by adsorbtion onto a 
column of anti-Src monoclonal antibody 327 (from J. 
Brugge, Ariad) followed by elution with glycine buffer, 
pH 2.2. 
2.3. Elution and trypsinization of EGF-R proteins in 
preparation for HPLC or thin layer chromatography 
The 32 P-labeled EGF-R protein bands were eluted from 
crushed gel pieces by agitating overnight with 50 mM 
NH4HCO3, pH 8.0, containing 5% 2-mercapatoethanol 
(BME) and 0.5% SDS. Myelin Basic Protein (80 /xg as a 
carrier protein) was added to the supernatants (gel parts 
removed by centrifugation) and the mixture was incubated 
on ice. Ice-cold TCA was added to reach 20% final 
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Fig. 1. pp60 vsr~ phosphorylation f kinase-defective and wild-type EGF- 
Rs in vitro. B82L mouse parental cells, B82L cells overexpressing either 
the wild-type (B82L K+)  or kinase-defective (B82L K-) human EGF 
receptor, and RatlB cells overexpressing pp60 vsrc were grown to conflu- 
ence before being lysed. EGF-R ~'as immunoprecipitated from the B82L 
cell lysates using an EGF receptor specific monoclonal antibody (McAb 
108). pp60 v-src was immunoprecipitated from the Rl-v-src cell lysates 
using a pp60 v-src specific monoclonal antibody (EC10). The EGF-R 
immunoprecipitations were then used either alone or combined with the 
v-Src immunoprecipitations to perform in vitro kinase assays using 
[3~-32p] ATP. The proteins were analyzed by SDS-PAGE and exposed to 
film. 
concentration a d the samples were incubated on ice for 1 
h. The TCA precipitated proteins were centrifuged for 10 
min and supernatant was discarded. The proteins were 
washed twice with ethanol and allowed to air dry. The 
tryptic phosphopeptides were oxidized by treatment with 
ice cold performic acid (made from 90% formic acid 
(88%) and 10% hydrogen peroxide incubated 30-60 min 
at room temperature) for 2 h at 4°C. Distilled H20 was 
added to the samples which were then lyophilized until 
dry; the H20 washing was repeated until all salts were 
removed. 15 /xl of 1 mg/ml TPCK-trypsin (Worthington) 
was added to the lyophilized samples and incubated at 
37°C overnight. 10/xl of trypsin was added two times over 
the next 12 hours. DdH20 was then added to the samples 
and the samples were lyophilized until dry; H20 washings 
and lyophilization were repeated three times. The washed 
proteins were then resuspended in either pH 1.9 buffer (for 
thin layer chromatography) or 0.05% trifluoroacetic acid, 
TFA (for HPLC). 
2.4. Thin layer chromatography 
Tryptic peptides were suspended in 5-10 ml pH 1.9 
buffer (7.8% (v/v)  glacial acetic acid and 2.5% (v/v)  
formic acid (88%)) and spotted onto cellulose plates (Kodak 
cellulose sheets without fluorescent indicator, Rochester, 
NY). Samples were separated in two dimensions by elec- 
trophoresis (~ 700 V for 1 h) and then by chromatography 
in tanks containing 200 ml n-butanol/pyridine/glacial 
acetic acid/water (75:50:15:60). thin layer chromatog- 
raphy data presented is representative of at least two 
independent experiments. 
2.5. HPLC phosphopeptide analysis 
Tryptic peptides were resolved by reverse-phase HPLC, 
using a Vydac C18 column (4.6 × 250 mm) and eluted 
with increasing concentrations of acetonitrile (0 to 80% in 
0.05% TFA) at a flow rate of 1 ml/min, as described by 
Wasilenko et al. [1]. HPLC was performed on an ABI 120 
apparatus at the University of Virginia Biomolecular Re- 
search Facility. 500 ml fractions were collected, and 
Cerenkov counts of each fraction were determined. 
2.6. Edman cycling of 32p-labeled EGF-R tryptic peptides 
HPLC fractions of 32 P-labeled tryptic phosphopeptides 
were subjected to automated Edman degradation at the 
University of Virginia Biomolecular Research Facility. 
Phosphorylated peptides were coupled to a Sequelon aryl 
amine membrane [11], washed 4 × with 27% acetonitrile, 
9% TFA and twice with 50% methanol, and then trans- 
ferred to an applied Biosystems 470A sequenator [12]. The 
cycle used for sequencing was as described [13], but 
modified for direct collection of anilinothiazolinone (ATZ) 
amino acids in 100% TFA [14]. Radioactivity was mea- 
sured by Cerenkov counting. 
3. Results 
3.1. pp60 src can directly phosphorylate kinase-defective 
and wild-type EGF-Rs in vitro 
To determine whether v-Src can directly phosphorylate 
EGF-Rs in vitro, wild-type and kinase-defective EGF-Rs 
were immunoprecipitated from B82L cells and the EGF-R 
immunoprecipitates were subjected to phosphorylation by 
v-Src (immunoprecipitated from R1 v-Src fibroblasts) or 
purified Baculovirus c-Src (which is constitutively active 
due to a lack of phosphorylation on the regulatory Tyr 
527). In the absence of pp60 Src, wild-type EGF-Rs dis- 
played in vitro autokinase activity, but kinase-defective 
EGF-Rs did not; however, in the presence of v-Src (or 
c-Src, data not shown), both wild-type and kinase-defec- 
tive EGF-Rs became phosphorylated (Fig. 1). Since ki- 
nase-defective EGF-Rs do not autophosphorylate, the32 p_ 
incorporation i to kinase-defective EGF-Rs must be due to 
the tyrosine kinase activity of pp60 Src. 
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Fig. 2. Thin layer chromatography of the phosphorylated EGF-R tryptic peptides. The EGF-R immunoprecipitates were used either alone or combined with 
32 the v-Src immunoprecipitates or baculovirus purified c-Src to perform in vitro kinase assays with [3,- P] ATP. The immunoprecipated proteins were 
analyzed by SDS-PAGE, and the gel was exposed to film. The 32 P-labeled proteins which corresponded in molecular weight o EGF-R were cut out and 
eluted from the gel. TCA precipitated 32P-labeled EGF-Rs, along with cartier protein (MBP), was trypsinized and the tryptic peptides were separated by 
two-dimensional thin layer chromatography. A. Wild-type EGF-R autophosphorylation. B. Kinase-defective EGF-R phosphorylated by immunoprecipated 
v-Src. C. Kinase-defective EGF-R phosphorylated by purified baculovirus c-Src. D. Tryptic peptides of kinase-defective EGF-R phosphorylated by
immunoprecipated v-Src mixed with the '28 min' HPLC fraction from Fig. 3. 
3.2. pp60 src phosphorylates the EGF-R on two sites in 
vitro 
Reverse-phase high performance liquid chromatography 
(HPLC) and phosphoamino acid analysis techniques were 
previously used to determine that v-Src-induced phospho- 
rylation of the EGF-R in vivo occurred on two tryptic 
phosphopeptides which are distinct from tryptic peptides 
known to contain autophosphorylation sites [1]. The two 
potential v-Src-induced phosphorylation sites were called 
Fig. 3. HPLC of the phosphorylated EGF-R tryptic peptides. EGF-Rs were immunoprecipitated from B82L K + cells and were then used either alone or 
combined with the v-Src immunoprecipitates or baculovirus purified c-Src to perform in vitro kinase assays with [3, -32 P]ATP. The immunoprecipated 
proteins were analyzed by SDS-PAGE, and the gel was exposed to film. The 32 P-labeled bands which corresponded in molecular weight o EGF-R were 
cut out and eluted from the gel. TCA precipitated 32P-labeled EGF-Rs, along with carrier protein (MBP), was trypsinized and the tryptic peptides were 
resolved by reverse-phase HPLC (0.05% TFA) using an ABI 120 apparatus at the University of Virginia, Biomolecular Research Facility. The level of 
radioactivity (Cerenkov) (left ordinate) and the acetonitfile concentration (right ordinate) of each 500 ml fraction were determined. (A) In vitro 
autophosphoryaltion of wild-type EGF-Rs. (B) In vitro phosphorylation f wild-type EGF-Rs by v-Src. (C) In vitro phosphorylation f kinase-defective 
EGF-Rs by v-Src. 
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'sPYI' and 'sPY2', for src  phosphotyrosine 1 and 2. 
Although the sequences of in vivo 'sPYI' and 'sPY2' have 
not been directly determined, the HPLC elution profile of 
'sPYI' and co-migration with a synthetic peptide suggest 
that this in vivo phosphorylation site could be tyrosine 845 
[1,15]. 
To characterize the pp60SrC-induced in vitro sites of 
phosphorylation on wild-type and kinase-defective EGF- 
Rs, thin layer chromatography and HPLC phosphopeptide 
mapping were performed. The thin layer chromatographic 
separation of tryptic peptides from autophosphorylated 
wild-type EGF-Rs in the absence of pp60 src is shown in 
Fig. 2A. There are five peptides which become promi- 
nently phosphorylated following in vitro autophosphoryla- 
tion of wild-type EGF-Rs (Fig. 2A); it is very likely that 
these phosphopeptides correspond to the five known in 
vivo sites of autophosphorylation on the EGF-R. In addi- 
tion, a weaker phosphorylation is seen at a spot (sPY2) 
which is a prominent site of phosphorylation by Src (see 
Fig. 2 B,C,D and text below). 
To investigate pp60sr%induced phosphorylation f EGF- 
Rs in the absence of receptor autophosphorylation, ki ase- 
defective EGF-Rs were used as substrates for either v-Src 
(immunoprecipitated from R1 v-Src fibroblasts) or purified 
Baculovirus c-Src. The thin layer chromatography separa- 
tion of tryptic peptides from kinase-defective EGF-Rs 
which had been phosphorylated by either immunoprecip- 
itated pp60 . . . . .  or purified Baculovirus pp60 c .... are shown 
in Fig. 2B and C. As indicated by the two spots, both v-Src 
and c-Src can phosphorylate kinase-defective EGF-Rs on 
at least two sites in vitro. One of the sites appears to 
comigrate with a major autophosphorylation site, as seen 
in Fig. 2A. Therefore, v-Src or c-Src may phosphorylate 
one autophosphorylation siteand one additional site on the 
EGF-R in vitro. 
In vitro phosphorylated EGF-R tryptic peptides were 
also separated by HPLC and were compared to published 
separations of in vivo and in vitro phosphorylations. HPLC 
analysis was performed on a Perkin-Elmer Series 4 appara- 
tus (data not shown) and on an ABI 120 apparatus (Fig. 3). 
The phosphopeptide elution profiles for EGF-Rs phospho- 
rylated by v-Src or c-Src in vitro were similar for both 
systems. 
HPLC profiles demonstrate hat both v-Src (Fig. 3) and 
c-Src (data not shown) can induce phosphorylation of 
wild-type EGF-Rs on at least one site that is not promi- 
nently autophosphorylated when comparing wild-type 
EGF-R autophosphorylation (Fig. 3A) to wild-type EGF-Rs 
which have been phosphorylated by v-Src (Fig. 3B). Con- 
sistent with the thin layer chromatography data (Fig. 2B 
and 2C), there appear to be two sites of pp60 ..... -induced 
phosphorylation  kinase-defective EGF-Rs, as indicated 
by two prominent peaks seen on the HPLC profile of 
kinase-defective EGF-Rs phosphorylated by v-Src in vitro 
(Fig. 3C). One of these peaks (at 22.5 min) appears to 
comigrate with an in vitro autophosphorylation peak (the 
first prominent peak in Fig. 3A) and also corresponds in
mobility to a known in vivo autophosphorylation peak, 
'PI '  [4,1]. The other peak (at 27.5 min) does not corre- 
spond to a known autophosphorylation peak, but does have 
an elution profile which is similar to a peak previously 
named 'sPY2' (for src  phosphotyrosine 2) which is phos- 
phorylated in v-Src transformed cells [1]. Therefore, the 
two v-Src-induced phosphorylation peaks on the EGF-R in 
Fig. 3 have been termed for purposes of this paper in vitro 
'PI '  and in vitro 'sPY2'. 
In order to identify which EGF-R phosphopeptide on
thin layer chromatography corresponds to the novel v-Src- 
induced phosphopeptide s parated by HPLC, the in vitro 
'sPY2' fraction (eluting at 27.5 min in Fig. 3) was mixed 
with kinase-defective EGF-R tryptic peptides which had 
been phosphorylated by v-Src in vitro. This peptide mix- 
ture was separated by thin layer chromatography (Fig. 2D). 
Of the two possible sites (as indicated on Fig. 2B and 2C), 
• 32  • the lower right spot showed an increase m P-incorpora- 
tion in relation to the other spot, indicating that the lower 
right spot corresponds to 'sPY2' on the HPLC profile• 
Similar mixing experiments were also done with the 'PI '  
peptide (data not shown) which eluted at 22.5 min on Fig. 
3. The 'PI '  HPLC peak was found to correspond to the 
upper left spot on thin layer chromatography. 
To identify which tyrosines on the EGF-R are phospho- 
rylated by v-Src in vitro, sequential Edman degradation 
was performed (Fig. 4) on the phosphopeptides eluting at 
22.5, 27.5 and 34.5 min (corresponding to the in vitro 'PI '  
and 'sPY2' peaks, as well as the in vitro 'P2' autophos- 
phorylation peak on Fig. 3). Edman degradation removes 
amino acids from the N-terminus individually; therefore, 
the radioactivity present on each amino acid can be mea- 
sured sequentially. When Edman degradation was per- 
formed on the pooled '22 min' and '22.5 min' fractions 
(from Fig. 3B), most of the 32p was removed on the 9th 
cycle, indicating that the in vitro 'PI '  corresponds to an 
EGF-R tryptic peptide containing a tyrosine at position 9. 
As indicated in Table 1, the known in vivo 'PI '  autophos- 
phorylation site is on Tyr 1173 and is located on the 9th 
position of the corresponding EGF-R tryptic peptide. In 
fact, the tryptic peptide containing Tyr 1173 is the only 
intracellular EGF-R tryptic peptide which has a tyrosine at 
the 9th position. Therefore, the in vitro 'PI '  (which elutes 
at 22.5 min and is also phosphorylated by v-Src in vitro) 
and the known in vivo 'PI '  are most likely the same 
EGF-R tryptic peptide which contains a phosphorylation 
site at Tyr 1173. 
Edman degradation was also performed on the in vitro 
'P2' autophosphorylation peak, to see whether the in vitro 
'P2' corresponds to the known in vivo 'P2' autophospho- 
rylation peak of the EGF-R. When Edman degradation was 
performed on the in vitro 'P2' ('34.5 min' fraction of Fig. 
3B), most of the 32p was released on the 12th cycle. There 
are three tryptic peptides located within the intracellular 
domain of the EGF-R which contain a tyrosine at the 12th 
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Fig. 4. Edman degradation of peptides 'PI ' ,  'P2', and 'sPY2'. Edman 
degradation was done on the HPLC-enriched tryptic peptides correspond- 
ing to 'PI ' ,  'P2', and 'sPY2' of the 'K+ EGF-R +v-Src' profile in Fig. 
3. The cycle number with the highest 32p cpm released corresponds to a 
phosphorylated residue at that position in the peptide analyzed. 
position. However, one of these peptides contains Tyr 
1148 at the 12th position and Tyr 1148 is the known in 
vivo 'P2' site of autophosphorylation  the EGF-R. 
Therefore, the in vitro 'P2' (which elutes at 34.5 min and 
is autophosphorylated by the EGF-R in vitro) and the 
known in vivo 'P2' are most likely the same the EGF-R 
tryptic peptide, which is phosphorylated on Tyr 1148. 
To identify the EGF-R in vitro 'sPY2' site, Edman 
degradation was performed on the pooled '27.5 min' and 
'28 min' fractions (Fig. 3B). Most of the 32p was removed 
on the 1 lth cycle of this fraction. As indicated in Table 1, 
there are two tryptic peptides located within the intra- 
cellular domain of the EGF-R which contain a tyrosine at 
the l lth position. One possibility is the tryptic peptide 
which contains Tyr 703; the other is a longer peptide 
which contains Tyr 876 on the 1 lth position. Based on the 
size and charge of each peptide, the peptide containing Tyr 
703 is the most likely to be the 'sPY2' peptide eluting at 
27.5-28 min. In addition, a phosphopeptide corresponding 
to the tryptic phosphopeptide containing Tyr 703 was 
synthesized at the University of Virginia Biomolecular 
Research Facility and analyzed by HPLC. It was found 
that the synthetic phosphopeptide eluted at a similar aceto- 
nitrile concentration (peaking at ~ 28.6 min) as the in 
vitro 'sPY2' tryptic phosphopeptide in Fig. 3. Therefore, 
we conclude that v-Src-induced in vitro phosphorylation f 
the EGF-R occurs on a novel site located at Tyr 703, as 
well as an autophosphorylation sitelocated at Tyr 1173. 
4. Discussion 
Receptor tyrosine kinases are generally activated in 
response to binding of ligand to an extracellular domain, 
whereas non-receptor tyrosine kinases are widely thought 
to be coupled to receptors which lack intrinsic tyrosine 
kinase activity. Recently, however, it has become clear that 
non-receptor tyrosine kinases interact functionally and bio- 
chemically with receptor tyrosine kinases. For example, 
over-expression of pp60 c .... renders cells mitogenically 
hyper-responsive to EGF [16] and inhibition of Src-family 
kinases blocks mitogenesis n response to EGF, PDGF or 
CSF-1 [17]. In many tumor systems, Src-family kinases 
Table 1 
Candidates for in vitro v-src phosphorylation sites on EGF-R 
EGF receptor tryptic peptides 
P1 
P2 
1173 
gly ser thr ala glu asn ala glu tyr leu arg(preferential SHC binding site) 
1148 
gly ser his gin ile ser leu asp asn pro asp tyr gln gin asp phepheprolys 
Candidates for in vitro 'sPY2' 
703 
val leu gly ser gly ala phe gly thr val tyr lys 
867 876 
fie tyr thr his gin ser asp val trp ser tyr gly val thr val trp glu leu met thr phe gly ser lys 
Edman degradation has revealed that the in vitro 'PI ' ,  'P2' and 'sPY2' tryptic peptides contain phosphorylated residues at positions 9, 12 and 11 
respectively. As indicated, the in vivo 'P l '  is located at position 9 of the corresponding EGF-R tryptic peptide. In addition, the in vivo 'P2' is located at 
position 12 of the corresponding EGF-R tryptic peptide. There are two possible EGF-R tryptic peptides which contain a tyrosine at position 1 l, and these 
correspond to peptides containing either Tyr 703 or Tyr 876 
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and EGF-R family members are co-overexpressed, and this 
may be of functional importance in tumorigenesis [18,19]. 
These interactions are not limited to Src-related and EGF-R 
related kinases. For example, JAKs can be activated not 
only by cytokine receptors but also by the EGF-R [20] and 
the Insulin-like Growth Factor Receptor can be phospho- 
rylated and activated not only in response to ligand but 
also by Src [21]. Thus, these interactions between the two 
groups of tyrosine kinases may be of general significance 
for cellular egulation. 
This laboratory previously demonstrated that in cells 
transformed by Src the EGF-R became constitutively acti- 
vated and tyrosine phosphorylated ontwo sites which were 
distinct from the known autophosphorylation sites. How- 
ever, the identity of those sites was not determined nor was 
it clear whether Src might be directly responsible for those 
phosphorylations. As a first step in addressing these issues, 
we have mapped the EGF-R sites which are directly 
phosphorylated by Src in vitro. 
Even though transformation f cells by v-Src does not 
induce phosphorylation f EGF-Rs on autophosphorylation 
sites in vivo [1], Src does directly phosphorylate EGF-Rs 
on at least one autophosphorylation sitein vitro: v-Src and 
purified Baculovirus c-Src clearly phosphorylated kinase- 
defective EGF-Rs on Tyr 1173 in vitro. It is not clear what 
the basis is for the difference between the in vivo and in 
vitro results. It is possible that in vivo the 1173 site is 
masked in the absence of ligand by an EGF-R-associated 
protein, such as SHC or Eps8, and that these proteins are 
removed when the EGF-R is purified for the in vitro 
kinase reactions. Another possibility is that Src does phos- 
phorylate Tyr 1173 in vivo, but that a phosphatase (which 
would be absent in the in vitro reactions) rapidly and 
specifically dephosphorylates EGF-Rs at this site. 
In addition to Tyr 1173, v-Src also directly phospho- 
rylates another non-autophosphorylation site in vitro, which 
is referred to as in vitro 'sPY2'. There is considerable 
evidence indicating that this phosphorylation site is Tyr 
703. First of all, there are only two potential intracellular 
tryptic peptides which contain a tyrosine at the 1 lth posi- 
tion; one of these peptides contains Tyr 703 and the other 
contains Tyr 876. As mentioned in Results, the size and 
charge of the peptide containing Tyr 703 is more consis- 
tent with the elution profile of in vitro 'sPY2'. Secondly, 
when 'cycling' the in vitro 'sPY2' peptide, the major 
release of radioactivity was at position 11; however a 
small amount of radioactivity was also released at posi- 
tions 4 and 9. The 703 peptide contains a serine at position 
4 and a threonine at position 9, which could have become 
phosphorylated during the immunecomplex kinase reaction 
by trace contaminating kinases. By contrast, the 876 pep- 
tide does not contain phosphorylatable amino acids at 
those sites (Table 1). Finally, a synthetic phosphopeptide 
corresponding to the 703 peptide migrated on HPLC at a 
position equivalent to 'sPY2'. For all these reasons we 
believe that in vitro 'sPY2' is located at Tyr 703. 
Tyr 703 is located within a potentially interesting se- 
quence of the EGF-R. Engagement of the T cell antigen 
receptor (TCR) results in the activation of several tyrosine 
kinases, including Src family kinases. Activation of Lck 
and Fyn in T cells stimulates the tyrosine phosphorylation 
of tyrosine-based activation motifs, known as TAMs or 
ARAMs [22,23] within the z and CD3 chains of TCRs. 
Phosphorylated TAMs serve as binding motifs for two 
SH2 domains contained in the zeta-associated protein tyro- 
sine kinase, ZAP70. Binding of ZAP70 to TCR correlates 
with ZAP70 activation and is an essential component of 
TCR signaling. TAM is a 15-16 amino acid sequence 
motif consisting of 'YXX(L/I)  X(7.8 )YXX(L/I)'. Tyr 703 
within the EGF-R is located within a sequence of 'IXXL 
X 8 Y(703)XXL'. Although Tyr 703 would be the only 
phosphotyrosine r sidue within the EGF-R 'TAM-like' 
sequence, the sequence might mimic TCR TAMs. In other 
words, activated pp60 Src may phosphorylate EGF-Rs on 
Tyr 703 and create a binding site for SH2-containing 
signaling molecules, such as PLC-g. 
Although 'sPY2' becomes phosphorylated in Src-trans- 
formed cells and can be directly phosphorylated by Src in 
vitro, the in vivo 'sPYI' site does not become phospho- 
rylated by Src in vitro. It is possible that some aspect of 
the imrnunecomplex kinase reactions blocks the accessibil- 
ity of this site in vitro. For example, perhaps immuno- 
precipitation of EGF-Rs by monoclonal antibodies (such as 
McAbl08) affects the three-dimensional structure of the 
receptor. Conversely, it is also possible that Src is not the 
in vivo 'sPYI' kinase, but that another kinase is activated 
in v-Src transformed cells which is responsible for this 
v-Src-induced phosphorylation [15]. In any event, all three 
EGF-R tyrosine residues (Y703, Y845, and Yl173) may 
be involved in v-Src signaling to EGF-Rs. However, the 
functional consequences of v-Src induced phosphorylation 
at these sites remains to be determined by mutagenesis and 
expression studies. 
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